Salix Pharmaceuticals Ltd. (SLXP): Today's Featured Drugs Laggard
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
(
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.6%. By the end of trading, Salix Pharmaceuticals fell $1.32 (-1.9%) to $68.32 on average volume. Throughout the day, 652,672 shares of Salix Pharmaceuticals exchanged hands as compared to its average daily volume of 763,600 shares. The stock ranged in price between $67.49-$69.99 after having opened the day at $69.74 as compared to the previous trading day's close of $69.64. Other companies within the Drugs industry that declined today were:
(
), down 43.4%,
(
), down 5.0%,
(
TheStreet Recommends
), down 4.8% and
(
), down 4.3%.
Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices used in the treatment of various gastrointestinal diseases in the United States. Salix Pharmaceuticals has a market cap of $4.2 billion and is part of the health care sector. Shares are up 67.7% year to date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Salix Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.
TheStreet Ratings rates
Salix Pharmaceuticals
as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.
- You can view the full Salix Pharmaceuticals Ratings Report.
On the positive front,
(
), up 25.5%,
(
), up 20.8%,
(
), up 15.4% and
(
), up 13.0% , were all gainers within the drugs industry with
(
) being today's featured drugs industry leader.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null
